Ipratropium (Br)
Ipratropium (Br) Information

About Ipratropium (Br)

Ipratropium (Br) is a quaternary derivative of atropine and a cholinergic blocking agent. It was the first muscarinic receptor blocking agent to acheive wide therapetic use in a pressurized aerosol. Ipratropium (Br) is prepared by chemical synthesis and the racemate is used clinically. It causes dialatation of bronchiol and is used to treat asthma and obstructive pulmonary disease. Ipratropium (Br) is available for inhalational administration.

Indications

Ipratropium (Br) is primarily indicated in conditions like Asthma, Bronchospasm prophylaxis, Chronic obstructive pulmonary disease, Reversible airways obstruction, Rhinorrhea, and can also be given in adjunctive therapy as an alternative drug of choice in Rapid reversion to sinus ryhthm.

Contraindication

Ipratropium (Br) is contraindicated in conditions like Glucoma,Prostatic hypertrophy,Hypersensitivity,Urinary retention,Bladder obstruction.

Side Effects

The severe or irreversible adverse effects of Ipratropium (Br), which give rise to further complications include Tachycardia, Palpitation, Angina, Tremors, Arrythmia, Tachycardia.The signs and symptoms that are produced after the acute overdosage of Ipratropium (Br) include Palpitations, Increased heart rate.The symptomatic adverse reactions produced by Ipratropium (Br) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Constipation, Dry mouth, Blurred vision, Rashes, Urticaria, Dyspepsia, Nausea and vomiting, Nasal congestion, Backache, Nasal irritation, Urinary RetentionX, Urinary retention, Dry mouth, dizziness, dyspepsia, Anaphylaxia.

Warnings

Ipratropium should be used with caution in patients with medical history especially of glaucoma, prostate trouble or any allergy especially to atropine or other belladonna derivatives. It should be used with caution during pregnancy.

High Risk Groups

Drug should not be given to Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.